SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from SUNESIS PHARMACEUTICALS INC (VIRX) (CIK 0001061027) (VIRX) — Sep 27, 2005

SUNESIS PHARMACEUTICALS INC (VIRX) (CIK 0001061027)
Date: Sept. 27, 2005 · CIK: 0001061027 · Accession: 0001104659-05-045802

AI Filing Summary & Sentiment

File numbers found in text: 333-121646

Date
September 27, 2005
Author
Director
Form
CORRESP
Company
SUNESIS PHARMACEUTICALS INC (VIRX) (CIK 0001061027)

Letter

Re: Sunesis Pharmaceuticals, Inc.

September 26,

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Mail Stop 03-08

Washington, D.C. 20549

Attention: Ms. Suzanne Hayes

Registration Statement on Form S-1 (File No. 333-121646)

Ladies and Gentlemen:

As representative of the undersigned underwriters of the proposed initial public offering of up to 6,000,000 shares of common stock of Sunesis Pharmaceuticals, Inc. (the “Company”), we hereby join the Company’s request for acceleration of the above-referenced Registration Statement, requesting effectiveness for 9:00 A.M. (NYT) on September 27, 2005, or as soon thereafter as is practicable.

Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended, we wish to advise you that we have effected the following distribution of the Company’s Preliminary Prospectus dated September 1, 2005, through the date hereof:

Preliminary Prospectus dated September 1, 2005:

8,328 copies to prospective underwriters, institutional investors, dealers and others

The undersigned advise that they have complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

Very truly
yours,
LEHMAN
BROTHERS INC.

Show Raw Text
CORRESP
1
filename1.htm

September 26,
2005

Securities and Exchange
Commission

Division of
Corporation Finance

100 F Street, N.E.

Mail Stop 03-08

Washington,
D.C.  20549

Attention:  Ms. Suzanne Hayes

Re:          Sunesis
Pharmaceuticals, Inc.

Registration
Statement on Form S-1 (File No. 333-121646)

Ladies and Gentlemen:

As
representative of the undersigned underwriters of the proposed initial public
offering of up to 6,000,000 shares of common stock of Sunesis Pharmaceuticals,
Inc. (the “Company”), we hereby join the Company’s request for acceleration of
the above-referenced Registration Statement, requesting effectiveness for 9:00
A.M. (NYT) on September 27, 2005, or as soon thereafter as is practicable.

Pursuant to
Rule 460 of the General Rules and Regulations under the Securities Act of 1933,
as amended, we wish to advise you that we have effected the following
distribution of the Company’s Preliminary Prospectus dated September 1, 2005,
through the date hereof:

Preliminary Prospectus dated September 1, 2005:

8,328 copies
to prospective underwriters, institutional investors, dealers and others

The
undersigned advise that they have complied and will continue to comply with
Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

  Very truly
  yours,

  LEHMAN
  BROTHERS INC.

  SG COWEN & CO., LLC

  NEEDHAM
  & COMPANY, LLC

  BY:

  SG COWEN
  & CO., LLC

  BY:

    /s/
  Graham Powiss

  Graham
  Powiss,

  Managing
  Director